Bioprosthetic tricuspid valve replacement in carcinoid heart disease from primary ovarian carcinoid tumor

Toshimitsu Tsugu, Shiro Iwanaga, Mitsushige Murata, Keiichi Fukuda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Carcinoid heart disease (CHD) commonly occurs in association with primary gastrointestinal tract carcinoid tumors with hepatic metastases. Unlike primary gastrointestinal tract carcinoid tumors, primary ovarian carcinoid tumors may cause CHD without hepatic metastases, accounting for only 0.3 % of all carcinoid tumors. Only 37 cases of CHD from primary ovarian carcinoid tumors have been reported. We present a case of CHD in which tricuspid valve thickening and shortening led to reduced valve mobility with the resulting severe tricuspid regurgitation. Considering these characteristics of an abnormal tricuspid valve, we suspected CHD, but prosthetic valve replacement was performed without sufficient systemic examination before surgery. Two years after valve replacement, the patient underwent excision of a mass in the lower abdomen, which was diagnosed as an ovarian carcinoid tumor by histopathological examination. The patient has been observed for more than 3 years after tricuspid valve replacement. She has not experienced bioprosthetic valve leaflet degeneration or dysfunction, although it has been reported that bioprosthetic valves may degenerate in patients with carcinoid tumors. Sufficient systemic examinations should be performed to explore the cause of disease.

Original languageEnglish
Pages (from-to)401-403
Number of pages3
JournalJournal of Medical Ultrasonics
Volume42
Issue number3
DOIs
Publication statusPublished - 2015 Mar 12

Fingerprint

Carcinoid Heart Disease
Tricuspid Valve
Carcinoid Tumor
Gastrointestinal Tract
Neoplasm Metastasis
Tricuspid Valve Insufficiency
Liver
Abdomen

Keywords

  • Bioprosthetic valve replacement
  • Carcinoid heart disease
  • Cartinoid tumor
  • Echocardiography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Bioprosthetic tricuspid valve replacement in carcinoid heart disease from primary ovarian carcinoid tumor. / Tsugu, Toshimitsu; Iwanaga, Shiro; Murata, Mitsushige; Fukuda, Keiichi.

In: Journal of Medical Ultrasonics, Vol. 42, No. 3, 12.03.2015, p. 401-403.

Research output: Contribution to journalArticle

Tsugu, Toshimitsu ; Iwanaga, Shiro ; Murata, Mitsushige ; Fukuda, Keiichi. / Bioprosthetic tricuspid valve replacement in carcinoid heart disease from primary ovarian carcinoid tumor. In: Journal of Medical Ultrasonics. 2015 ; Vol. 42, No. 3. pp. 401-403.
@article{059ebcecea804ccf9008bc821ea804d3,
title = "Bioprosthetic tricuspid valve replacement in carcinoid heart disease from primary ovarian carcinoid tumor",
abstract = "Carcinoid heart disease (CHD) commonly occurs in association with primary gastrointestinal tract carcinoid tumors with hepatic metastases. Unlike primary gastrointestinal tract carcinoid tumors, primary ovarian carcinoid tumors may cause CHD without hepatic metastases, accounting for only 0.3 {\%} of all carcinoid tumors. Only 37 cases of CHD from primary ovarian carcinoid tumors have been reported. We present a case of CHD in which tricuspid valve thickening and shortening led to reduced valve mobility with the resulting severe tricuspid regurgitation. Considering these characteristics of an abnormal tricuspid valve, we suspected CHD, but prosthetic valve replacement was performed without sufficient systemic examination before surgery. Two years after valve replacement, the patient underwent excision of a mass in the lower abdomen, which was diagnosed as an ovarian carcinoid tumor by histopathological examination. The patient has been observed for more than 3 years after tricuspid valve replacement. She has not experienced bioprosthetic valve leaflet degeneration or dysfunction, although it has been reported that bioprosthetic valves may degenerate in patients with carcinoid tumors. Sufficient systemic examinations should be performed to explore the cause of disease.",
keywords = "Bioprosthetic valve replacement, Carcinoid heart disease, Cartinoid tumor, Echocardiography",
author = "Toshimitsu Tsugu and Shiro Iwanaga and Mitsushige Murata and Keiichi Fukuda",
year = "2015",
month = "3",
day = "12",
doi = "10.1007/s10396-015-0621-9",
language = "English",
volume = "42",
pages = "401--403",
journal = "Japanese Journal of Medical Ultrasonics",
issn = "1346-4523",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Bioprosthetic tricuspid valve replacement in carcinoid heart disease from primary ovarian carcinoid tumor

AU - Tsugu, Toshimitsu

AU - Iwanaga, Shiro

AU - Murata, Mitsushige

AU - Fukuda, Keiichi

PY - 2015/3/12

Y1 - 2015/3/12

N2 - Carcinoid heart disease (CHD) commonly occurs in association with primary gastrointestinal tract carcinoid tumors with hepatic metastases. Unlike primary gastrointestinal tract carcinoid tumors, primary ovarian carcinoid tumors may cause CHD without hepatic metastases, accounting for only 0.3 % of all carcinoid tumors. Only 37 cases of CHD from primary ovarian carcinoid tumors have been reported. We present a case of CHD in which tricuspid valve thickening and shortening led to reduced valve mobility with the resulting severe tricuspid regurgitation. Considering these characteristics of an abnormal tricuspid valve, we suspected CHD, but prosthetic valve replacement was performed without sufficient systemic examination before surgery. Two years after valve replacement, the patient underwent excision of a mass in the lower abdomen, which was diagnosed as an ovarian carcinoid tumor by histopathological examination. The patient has been observed for more than 3 years after tricuspid valve replacement. She has not experienced bioprosthetic valve leaflet degeneration or dysfunction, although it has been reported that bioprosthetic valves may degenerate in patients with carcinoid tumors. Sufficient systemic examinations should be performed to explore the cause of disease.

AB - Carcinoid heart disease (CHD) commonly occurs in association with primary gastrointestinal tract carcinoid tumors with hepatic metastases. Unlike primary gastrointestinal tract carcinoid tumors, primary ovarian carcinoid tumors may cause CHD without hepatic metastases, accounting for only 0.3 % of all carcinoid tumors. Only 37 cases of CHD from primary ovarian carcinoid tumors have been reported. We present a case of CHD in which tricuspid valve thickening and shortening led to reduced valve mobility with the resulting severe tricuspid regurgitation. Considering these characteristics of an abnormal tricuspid valve, we suspected CHD, but prosthetic valve replacement was performed without sufficient systemic examination before surgery. Two years after valve replacement, the patient underwent excision of a mass in the lower abdomen, which was diagnosed as an ovarian carcinoid tumor by histopathological examination. The patient has been observed for more than 3 years after tricuspid valve replacement. She has not experienced bioprosthetic valve leaflet degeneration or dysfunction, although it has been reported that bioprosthetic valves may degenerate in patients with carcinoid tumors. Sufficient systemic examinations should be performed to explore the cause of disease.

KW - Bioprosthetic valve replacement

KW - Carcinoid heart disease

KW - Cartinoid tumor

KW - Echocardiography

UR - http://www.scopus.com/inward/record.url?scp=84937252773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937252773&partnerID=8YFLogxK

U2 - 10.1007/s10396-015-0621-9

DO - 10.1007/s10396-015-0621-9

M3 - Article

C2 - 26576793

AN - SCOPUS:84937252773

VL - 42

SP - 401

EP - 403

JO - Japanese Journal of Medical Ultrasonics

JF - Japanese Journal of Medical Ultrasonics

SN - 1346-4523

IS - 3

ER -